GSK is willing to pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax.
British drugmaker GSK is looking to bolster its vaccine pipeline as it prepares to separate its consumer unit.
Last month, GSK appetite spent $1.9 billion to buy Sierra Oncology to bolster its cancer business.
U.S.-based Affinivax is developing next-generation vaccines. Affinivax has developed vaccines for pneumococcal diseases, including pneumonia, meningitis and sinusitis.
GSK will pay Affinivax $2.1 billion upfront and up to $1.2 billion in potential development milestones.
